Loading...
Header Logo
Keywords
Last Name
Institution

JAMES P ALLISON

TitleProfessor
InstitutionMD Anderson
DepartmentImmunology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Sharma N, Vacher J, Allison JP. TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. Proc Natl Acad Sci U S A. 2019 May 21; 116(21):10453-10462. PMID: 31076558.
      View in: PubMed
    2. Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP. Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States. Immunity. 2019 Apr 16; 50(4):1084-1098.e10. PMID: 30926234.
      View in: PubMed
    3. Allison J. Why What You May Not Know About Fecal Immunochemical Testing Matters. Ann Intern Med. 2019 Feb 26. PMID: 30802903.
      View in: PubMed
    4. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697. PMID: 30635425.
      View in: PubMed
    5. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2019 Jan; 25(1):188. PMID: 30479380.
      View in: PubMed
    6. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941. PMID: 30361510.
      View in: PubMed
    7. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942. PMID: 30361511.
      View in: PubMed
    8. Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, Ravandi F, Jabbour EJ, Al-Hamal Z, Konopleva M, Ning J, Xiao L, Hidalgo Lopez J, Kornblau SM, Andreeff M, Flores W, Bueso-Ramos C, Blando J, Galera P, Calvo KR, Al-Atrash G, Allison JP, Kantarjian HM, Sharma P, Daver NG. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 May 01; 125(9):1470-1481. PMID: 30500073.
      View in: PubMed
    9. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018 12; 24(12):1804-1808. PMID: 30420754.
      View in: PubMed
    10. Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian H. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383. PMID: 30409776.
      View in: PubMed
    11. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654. PMID: 30297909.
      View in: PubMed
    12. Liang PS, Allison J, Ladabaum U, Martinez ME, Murphy CC, Schoen RE, Shaukat A, Tinmouth J, Gupta S. Potential Intended and Unintended Consequences of Recommending Initiation of Colorectal Cancer Screening at Age 45 Years. Gastroenterology. 2018 10; 155(4):950-954. PMID: 30138614.
      View in: PubMed
    13. Wei SC, Duffy CR, Allison JP. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018 Sep; 8(9):1069-1086. PMID: 30115704.
      View in: PubMed
    14. Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK, Allison JP, Zhao H, Sharma P. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 Aug 31; 128(9):3813-3818. PMID: 29905573.
      View in: PubMed
    15. Sharma A, Subudhi SK, Blando J, Scutti J, Vence L, Wargo J, Allison JP, Ribas A, Sharma P. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clin Cancer Res. 2019 Feb 15; 25(4):1233-1238. PMID: 30054281.
      View in: PubMed
    16. Alsayid M, Singh MH, Issaka R, Laleau V, Day L, Lee J, Allison J, Somsouk M. Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light. Clin Gastroenterol Hepatol. 2018 Oct; 16(10):1593-1597.e1. PMID: 29660528.
      View in: PubMed
    17. Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, Kantarjian H. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018 05; 32(5):1094-1105. PMID: 29487386.
      View in: PubMed
    18. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193. PMID: 29361468.
      View in: PubMed
    19. Ariyan CE, Brady MS, Siegelbaum RH, Hu J, Bello DM, Rand J, Fisher C, Lefkowitz RA, Panageas KS, Pulitzer M, Vignali M, Emerson R, Tipton C, Robins H, Merghoub T, Yuan J, Jungbluth A, Blando J, Sharma P, Rudensky AY, Wolchok JD, Allison JP. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018 02; 6(2):189-200. PMID: 29339377.
      View in: PubMed
    20. Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res. 2018 03 01; 24(5):1011-1018. PMID: 29246938.
      View in: PubMed
    21. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE, Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451. PMID: 28878208.
      View in: PubMed
    22. Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017 Sep 07; 170(6):1120-1133.e17. PMID: 28803728.
      View in: PubMed
    23. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097. PMID: 28733428.
      View in: PubMed
    24. Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018 04; 59(4):790-802. PMID: 28679300.
      View in: PubMed
    25. Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. J Immunol. 2017 08 01; 199(3):974-981. PMID: 28646041.
      View in: PubMed
    26. Carstens JL, Correa de Sampaio P, Yang D, Barua S, Wang H, Rao A, Allison JP, LeBleu VS, Kalluri R. Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun. 2017 04 27; 8:15095. PMID: 28447602.
      View in: PubMed
    27. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35. PMID: 28428884.
      View in: PubMed
    28. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med. 2017; 2. PMID: 28819565.
      View in: PubMed
    29. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, Zhao H, Chen J, Chen H, Efstathiou E, Troncoso P, Allison JP, Logothetis CJ, Wistuba II, Sepulveda MA, Sun J, Wargo J, Blando J, Sharma P. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555. PMID: 28346412.
      View in: PubMed
    30. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379). PMID: 28251903.
      View in: PubMed
    31. Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453. PMID: 28223062.
      View in: PubMed
    32. Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340. PMID: 28194010.
      View in: PubMed
    33. Haymaker CL, Kim D, Uemura M, Vence LM, Phillip A, McQuail N, Brown PD, Fernandez I, Hudgens CW, Creasy C, Hwu WJ, Sharma P, Tetzlaff MT, Allison JP, Hwu P, Bernatchez C, Diab A. Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. Cancer Immunol Res. 2017 02; 5(2):100-105. PMID: 28062513.
      View in: PubMed
    34. Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, Krishnan S, Allison JP, Sharma P, Hwu P, Komaki R, Overwijk WW, Gomez DR, Chang JY, Hahn SM, Cortez MA, Welsh JW. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850. PMID: 27821490.
      View in: PubMed
    35. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):11919-11924. PMID: 27698113.
      View in: PubMed
    36. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9. PMID: 27667683.
      View in: PubMed
    37. Uemura M, Trinh VA, Haymaker C, Jackson N, Kim DW, Allison JP, Sharma P, Vence L, Bernatchez C, Hwu P, Diab A. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. J Hematol Oncol. 2016 09 05; 9(1):81. PMID: 27595932.
      View in: PubMed
    38. Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, Diab A, Sung J, Maybody M, Morris E, Brogi E, Morrow M, Sacchini V, Elemento O, Robins H, Patil S, Allison JP, Wolchok JD, Hudis C, Norton L, McArthur HL. Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer Immunol Res. 2016 10; 4(10):835-844. PMID: 27587469.
      View in: PubMed
    39. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632. PMID: 27572267.
      View in: PubMed
    40. McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L. A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clin Cancer Res. 2016 Dec 01; 22(23):5729-5737. PMID: 27566765.
      View in: PubMed
    41. Shi LZ, Fu T, Guan B, Chen J, Blando JM, Allison JP, Xiong L, Subudhi SK, Gao J, Sharma P. Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335. PMID: 27498556.
      View in: PubMed
    42. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37. PMID: 27301722.
      View in: PubMed
    43. Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, Fu T, Sharma P, Allison JP, Feldman RM. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection. Cancer Res. 2016 07 01; 76(13):3684-9. PMID: 27197182.
      View in: PubMed
    44. Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunol Res. 2016 Apr; 4(4):279-88. PMID: 27036972.
      View in: PubMed
    45. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 2016 Mar; 5(3):e1136044. PMID: 27141370.
      View in: PubMed
    46. Allison J, Neill US. A conversation with James Allison. J Clin Invest. 2016 Jan; 126(1):3-4. PMID: 26727227.
      View in: PubMed
    47. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell. 2015 Dec 14; 28(6):831-833. PMID: 28843279.
      View in: PubMed
    48. Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015 Oct 13; 13(2):412-24. PMID: 26411680.
      View in: PubMed
    49. Allison JP. Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award. JAMA. 2015 Sep 15; 314(11):1113-4. PMID: 26348357.
      View in: PubMed
    50. Allison JP. Checkpoints. Cell. 2015 Sep 10; 162(6):1202-5. PMID: 26359978.
      View in: PubMed
    51. Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015 Sep 22; 112(38):E5290-9. PMID: 26351680.
      View in: PubMed
    52. Seyedin SN, Schoenhals JE, Lee DA, Cortez MA, Wang X, Niknam S, Tang C, Hong DS, Naing A, Sharma P, Allison JP, Chang JY, Gomez DR, Heymach JV, Komaki RU, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980. PMID: 26310908.
      View in: PubMed
    53. Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu CC, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, Nischal H, Allison JP, Zeisberg M, Kalluri R. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015 Sep; 21(9):998-1009. PMID: 26236991.
      View in: PubMed
    54. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    55. Kreymborg K, Haak S, Murali R, Wei J, Waitz R, Gasteiger G, Savage PA, van den Brink MR, Allison JP. Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunol Res. 2015 Aug; 3(8):849-54. PMID: 26122284.
      View in: PubMed
    56. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77. PMID: 26069186.
      View in: PubMed
    57. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015 Apr 09; 161(2):205-14. PMID: 25860605.
      View in: PubMed
    58. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015 Apr 03; 348(6230):56-61. PMID: 25838373.
      View in: PubMed
    59. Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknect E, Murphy WJ, Serody JS, Munn DH, Freeman GJ, Allison JP, Mak TW, van den Brink M, Zeiser R, Blazar BR. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015 May 21; 125(21):3335-46. PMID: 25814530.
      View in: PubMed
    60. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Mar; 25(3):399-400. PMID: 25732764.
      View in: PubMed
    61. Pedicord VA, Cross JR, Montalvo-Ortiz W, Miller ML, Allison JP. Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. J Immunol. 2015 Mar 01; 194(5):2089-98. PMID: 25624453.
      View in: PubMed
    62. Hannani D, Vétizou M, Enot D, Rusakiewicz S, Chaput N, Klatzmann D, Desbois M, Jacquelot N, Vimond N, Chouaib S, Mateus C, Allison JP, Ribas A, Wolchok JD, Yuan J, Wong P, Postow M, Mackiewicz A, Mackiewicz J, Schadendorff D, Jaeger D, Zörnig I, Hassel J, Korman AJ, Bahjat K, Maio M, Calabro L, Teng MW, Smyth MJ, Eggermont A, Robert C, Kroemer G, Zitvogel L. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res. 2015 Feb; 25(2):208-24. PMID: 25582080.
      View in: PubMed
    63. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014 Nov 27; 515(7528):577-81. PMID: 25428507.
      View in: PubMed
    64. Tang C, Wang X, Soh H, Seyedin S, Cortez MA, Krishnan S, Massarelli E, Hong D, Naing A, Diab A, Gomez D, Ye H, Heymach J, Komaki R, Allison JP, Sharma P, Welsh JW. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8. PMID: 25187273.
      View in: PubMed
    65. Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP. Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility. Cancer Immunol Res. 2014 Oct; 2(10):970-80. PMID: 25038199.
      View in: PubMed
    66. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014 Jun 16; 25(6):719-34. PMID: 24856586.
      View in: PubMed
    67. Green BB, Coronado GD, Devoe JE, Allison J. Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health. 2014 Jun; 104(6):982-6. PMID: 24825195.
      View in: PubMed
    68. Fan X, Quezada SA, Sepulveda MA, Sharma P, Allison JP. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J Exp Med. 2014 Apr 07; 211(4):715-25. PMID: 24687957.
      View in: PubMed
    69. Gupta S, Sussman DA, Doubeni CA, Anderson DS, Day L, Deshpande AR, Elmunzer BJ, Laiyemo AO, Mendez J, Somsouk M, Allison J, Bhuket T, Geng Z, Green BB, Itzkowitz SH, Martinez ME. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014 Apr; 106(4):dju032. PMID: 24681602.
      View in: PubMed
    70. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014 Mar 05; 6(226):226ra32. PMID: 24598590.
      View in: PubMed
    71. Day LW, Bhuket T, Allison J. FIT testing: an overview. Curr Gastroenterol Rep. 2013 Nov; 15(11):357. PMID: 24218070.
      View in: PubMed
    72. Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014; 65:185-202. PMID: 24188664.
      View in: PubMed
    73. Kitano S, Tsuji T, Liu C, Hirschhorn-Cymerman D, Kyi C, Mu Z, Allison JP, Gnjatic S, Yuan JD, Wolchok JD. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. Cancer Immunol Res. 2013 Oct; 1(4):235-44. PMID: 24396833.
      View in: PubMed
    74. Reis BS, Jungbluth AA, Frosina D, Holz M, Ritter E, Nakayama E, Ishida T, Obata Y, Carver B, Scher H, Scardino PT, Slovin S, Subudhi SK, Reuter VE, Savage C, Allison JP, Melamed J, Jäger E, Ritter G, Old LJ, Gnjatic S. Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. Clin Cancer Res. 2013 Nov 15; 19(22):6112-25. PMID: 24081977.
      View in: PubMed
    75. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res. 2013 Oct; 1(4):229-34. PMID: 24777852.
      View in: PubMed
    76. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26; 210(9):1695-710. PMID: 23897981.
      View in: PubMed
    77. Atala A. Re: Aire-dependent thymic development of tumor-associated regulatory T cells. J Urol. 2013 Nov; 190(5):1954. PMID: 24120816.
      View in: PubMed
    78. Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O'Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013 Jul; 1291:1-13. PMID: 23772560.
      View in: PubMed
    79. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013 Jul 01; 210(7):1389-402. PMID: 23752227.
      View in: PubMed
    80. Gyorki DE, Yuan J, Mu Z, Zaidi B, Pulitzer M, Busam K, Brady MS, Coit DG, Allison JP, Wolchok JD, Ariyan CE. Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol. 2013 Sep; 20(9):3106-11. PMID: 23681603.
      View in: PubMed
    81. Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC, Allison JP. Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin. J Exp Med. 2013 Apr 08; 210(4):743-55. PMID: 23547098.
      View in: PubMed
    82. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, Amit AS, Kang C, Geddes JE, Allison JP, Socci ND, Savage PA. Aire-dependent thymic development of tumor-associated regulatory T cells. Science. 2013 Mar 08; 339(6124):1219-24. PMID: 23471412.
      View in: PubMed
    83. Gupta S, Tong L, Anderson P, Rose B, Carter E, Koch M, Argenbright K, Ahn C, Allison J, Skinner CS. Measurement of colorectal cancer test use with medical claims data in a safety-net health system. Am J Med Sci. 2013 Feb; 345(2):99-103. PMID: 22814361.
      View in: PubMed
    84. Corse E, Gottschalk RA, Park JS, Sepulveda MA, Loke P, Sullivan TJ, Johnson LK, Allison JP. Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand. J Immunol. 2013 Jan 15; 190(2):526-30. PMID: 23248264.
      View in: PubMed
    85. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012 Oct 03; 10:205. PMID: 23034130.
      View in: PubMed
    86. Mineharu Y, Muhammad AK, Yagiz K, Candolfi M, Kroeger KM, Xiong W, Puntel M, Liu C, Levy E, Lugo C, Kocharian A, Allison JP, Curran MA, Lowenstein PR, Castro MG. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-?B signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics. 2012 Oct; 9(4):827-43. PMID: 22996231.
      View in: PubMed
    87. Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi YM, Loke P, Lin J, Yuan J, Serreze DV, Allison JP, Zang X. B7x in the periphery abrogates pancreas-specific damage mediated by self-reactive CD8 T cells. J Immunol. 2012 Oct 15; 189(8):4165-74. PMID: 22972920.
      View in: PubMed
    88. Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol. 2012 Aug 01; 189(3):1123-7. PMID: 22753941.
      View in: PubMed
    89. Waitz R, Fassò M, Allison JP. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. Oncoimmunology. 2012 Jul 01; 1(4):544-546. PMID: 22754781.
      View in: PubMed
    90. Zhang M, Ju W, Yao Z, Yu P, Wei BR, Simpson RM, Waitz R, Fassò M, Allison JP, Waldmann TA. Augmented IL-15Ra expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice. J Immunol. 2012 Jun 15; 188(12):6156-64. PMID: 22593619.
      View in: PubMed
    91. Srivastava PK, Cerundolo V, Knuth A, Allison JP. An open invitation to the cancer immunology community. Cancer Immun. 2012; 12:1. PMID: 22896746.
      View in: PubMed
    92. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012; 12:14. PMID: 22896759.
      View in: PubMed
    93. Jenq RR, Curran MA, Goldberg GL, Liu C, Allison JP, van den Brink MR. Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer. PLoS One. 2012; 7(4):e35222. PMID: 22493742.
      View in: PubMed
    94. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, Allison JP, Waldmann TA. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012 Apr 17; 109(16):6187-92. PMID: 22474386.
      View in: PubMed
    95. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012 Mar 08; 366(10):925-31. PMID: 22397654.
      View in: PubMed
    96. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012 Feb 08; 482(7385):400-4. PMID: 22318521.
      View in: PubMed
    97. Sharma P, Allison JP. Retrospective. Lloyd J. Old (1933-2011). Science. 2012 Jan 06; 335(6064):49. PMID: 22223799.
      View in: PubMed
    98. Gottschalk RA, Hathorn MM, Beuneu H, Corse E, Dustin ML, Altan-Bonnet G, Allison JP. Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses. Proc Natl Acad Sci U S A. 2012 Jan 17; 109(3):881-6. PMID: 22223661.
      View in: PubMed
    99. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol. 2012 Feb 01; 188(3):976-80. PMID: 22198953.
      View in: PubMed
    100. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571.
      View in: PubMed
    101. Waitz R, Solomon SB, Petre EN, Trumble AE, Fassò M, Norton L, Allison JP. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012 Jan 15; 72(2):430-9. PMID: 22108823.
      View in: PubMed
    102. Curran MA, Callahan MK, Subudhi SK, Allison JP. Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2012 Jun; 217(6):590-2. PMID: 22459268.
      View in: PubMed
    103. Allison JP, Benoist C, Chervonsky AV. Nobels: Toll pioneers deserve recognition. Nature. 2011 Nov 09; 479(7372):178. PMID: 22071753.
      View in: PubMed
    104. Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011 Oct 24; 11(11):805-12. PMID: 22020206.
      View in: PubMed
    105. Krummel MF, Allison JP. Pillars article: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. The journal of experimental medicine. 1995. 182: 459-465. J Immunol. 2011 Oct 01; 187(7):3459-65. PMID: 21934097.
      View in: PubMed
    106. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, Xu Y, Pogoriler E, Terzulli SL, Kuk D, Panageas KS, Ritter G, Sznol M, Halaban R, Jungbluth AA, Allison JP, Old LJ, Wolchok JD, Gnjatic S. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A. 2011 Oct 04; 108(40):16723-8. PMID: 21933959.
      View in: PubMed
    107. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011 Aug 28; 17(9):1094-100. PMID: 21873989.
      View in: PubMed
    108. Donkor MK, Sarkar A, Savage PA, Franklin RA, Johnson LK, Jungbluth AA, Allison JP, Li MO. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-ß1 cytokine. Immunity. 2011 Jul 22; 35(1):123-34. PMID: 21757379.
      View in: PubMed
    109. Wei J, Loke P, Zang X, Allison JP. Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med. 2011 Aug 01; 208(8):1683-94. PMID: 21727190.
      View in: PubMed
    110. Corse E, Gottschalk RA, Allison JP. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol. 2011 May 01; 186(9):5039-45. PMID: 21505216.
      View in: PubMed
    111. Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev. 2011 May; 241(1):104-18. PMID: 21488893.
      View in: PubMed
    112. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011 Apr 29; 6(4):e19499. PMID: 21559358.
      View in: PubMed
    113. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother. 2011 Aug; 60(8):1137-46. PMID: 21465316.
      View in: PubMed
    114. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):266-71. PMID: 21173239.
      View in: PubMed
    115. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010 Oct; 37(5):473-84. PMID: 21074063.
      View in: PubMed
    116. Corse E, Gottschalk RA, Krogsgaard M, Allison JP. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 2010 Sep 14; 8(9). PMID: 20856903.
      View in: PubMed
    117. Gottschalk RA, Corse E, Allison JP. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med. 2010 Aug 02; 207(8):1701-11. PMID: 20660617.
      View in: PubMed
    118. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, Spriggs DR, Dupont J, Allison JP. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010 Aug; 23(8):1104-12. PMID: 20495537.
      View in: PubMed
    119. Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res. 2010 May 15; 16(10):2781-91. PMID: 20460483.
      View in: PubMed
    120. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010 May 15; 16(10):2861-71. PMID: 20460488.
      View in: PubMed
    121. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Apr 01; 116(7):1767-75. PMID: 20143434.
      View in: PubMed
    122. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010 Mar 02; 107(9):4275-80. PMID: 20160101.
      View in: PubMed
    123. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, Restifo NP, Allison JP. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010 Mar 15; 207(3):637-50. PMID: 20156971.
      View in: PubMed
    124. Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol. 2010 Jun; 22(3):326-32. PMID: 20116985.
      View in: PubMed
    125. Yuan J, Page DB, Ku GY, Li Y, Mu Z, Ariyan C, Gallardo HF, Roman RA, Heine AI, Terzulli SL, Ritter E, Gnjatic S, Ritter G, Jungbluth AA, Allison JP, Old LJ, Wolchok JD. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun. 2010 Jan 07; 10:1. PMID: 20052966.
      View in: PubMed
    126. Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res. 2009 Oct 01; 69(19):7747-55. PMID: 19738077.
      View in: PubMed
    127. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009 Sep 01; 15(17):5323-37. PMID: 19723653.
      View in: PubMed
    128. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug 03; 206(8):1717-25. PMID: 19581407.
      View in: PubMed
    129. Pentcheva-Hoang T, Corse E, Allison JP. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev. 2009 May; 229(1):67-87. PMID: 19426215.
      View in: PubMed
    130. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009 Jul; 157(1):9-19. PMID: 19659765.
      View in: PubMed
    131. Thompson RH, Kwon ED, Allison JP. Inhibitors of B7-CD28 costimulation in urologic malignancies. Immunotherapy. 2009 Jan; 1(1):129-39. PMID: 20445772.
      View in: PubMed
    132. Lin Y, Gallardo HF, Ku GY, Li H, Manukian G, Rasalan TS, Xu Y, Terzulli SL, Old LJ, Allison JP, Houghton AN, Wolchok JD, Yuan J. Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009; 11(7):912-22. PMID: 19903103.
      View in: PubMed
    133. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20410-5. PMID: 19074257.
      View in: PubMed
    134. Allison J, Herrinton LJ, Liu L, Yu J, Lowder J. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008 Sep; 6(9):999-1003. PMID: 18774533.
      View in: PubMed
    135. Pressman AR, Hutfless S, Velayos F, Fireman B, Lewis JD, Allison J, Abramson O, Herrinton LJ. Patterns of infliximab use among Crohn's disease patients in a community setting. Inflamm Bowel Dis. 2008 Sep; 14(9):1265-72. PMID: 18452199.
      View in: PubMed
    136. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med. 2008 Sep 01; 205(9):2125-38. PMID: 18725522.
      View in: PubMed
    137. Thompson RH, Zang X, Lohse CM, Leibovich BC, Slovin SF, Reuter VE, Cheville JC, Blute ML, Russo P, Kwon ED, Allison JP. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage. Cancer Res. 2008 Aug 01; 68(15):6054-8. PMID: 18676826.
      View in: PubMed
    138. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev. 2008 Aug; 224:141-65. PMID: 18759925.
      View in: PubMed
    139. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol. 2008 Aug; 103(8):1998-2006. PMID: 18796097.
      View in: PubMed
    140. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83. PMID: 18523152.
      View in: PubMed
    141. Fassò M, Waitz R, Hou Y, Rim T, Greenberg NM, Shastri N, Fong L, Allison JP. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A. 2008 Mar 04; 105(9):3509-14. PMID: 18303116.
      View in: PubMed
    142. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008 Feb 26; 105(8):3005-10. PMID: 18287062.
      View in: PubMed
    143. Segal NH, Parsons DW, Peggs KS, Velculescu V, Kinzler KW, Vogelstein B, Allison JP. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008 Feb 01; 68(3):889-92. PMID: 18245491.
      View in: PubMed
    144. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, VanRoey MJ, Allison JP, Jooss K. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother. 2008 Aug; 57(8):1263-70. PMID: 18236040.
      View in: PubMed
    145. Savage PA, Vosseller K, Kang C, Larimore K, Riedel E, Wojnoonski K, Jungbluth AA, Allison JP. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science. 2008 Jan 11; 319(5860):215-20. PMID: 18187659.
      View in: PubMed
    146. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, Reuter VE, Eastham JA, Scardino PT, Sharma P, Allison JP. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A. 2007 Dec 04; 104(49):19458-63. PMID: 18042703.
      View in: PubMed
    147. Pentcheva-Hoang T, Chen L, Pardoll DM, Allison JP. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A. 2007 Nov 06; 104(45):17765-70. PMID: 17968013.
      View in: PubMed
    148. Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE. Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol. 2007 Sep 15; 179(6):3926-36. PMID: 17785830.
      View in: PubMed
    149. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5271-9. PMID: 17875755.
      View in: PubMed
    150. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007 Sep; 12(3):192-9. PMID: 17785201.
      View in: PubMed
    151. Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. 2007 Aug 01; 110(3):954-61. PMID: 17483299.
      View in: PubMed
    152. Sharma P, Old LJ, Allison JP. Immunotherapeutic strategies for high-risk bladder cancer. Semin Oncol. 2007 Apr; 34(2):165-72. PMID: 17382800.
      View in: PubMed
    153. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, Cummings T, Allison JP, Bigner DD, Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007 Apr 01; 13(7):2158-67. PMID: 17404100.
      View in: PubMed
    154. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5. PMID: 17363537.
      View in: PubMed
    155. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD, Lary JW, Cole JL, Deng H, Xiao H, Dilorenzo TP, Allison JP, Nathenson SG, Almo SC. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity. 2007 Mar; 26(3):311-21. PMID: 17363302.
      View in: PubMed
    156. Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP. A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics. 2006 Dec; 88(6):841-845. PMID: 17014982.
      View in: PubMed
    157. Zang X, Allison JP. To be or not to be B7. J Clin Invest. 2006 Oct; 116(10):2590-3. PMID: 17016555.
      View in: PubMed
    158. Thompson RH, Allison JP, Kwon ED. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer. Urol Oncol. 2006 Sep-Oct; 24(5):442-7. PMID: 16962497.
      View in: PubMed
    159. Engelhardt JJ, Sullivan TJ, Allison JP. CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006 Jul 15; 177(2):1052-61. PMID: 16818761.
      View in: PubMed
    160. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul; 116(7):1935-45. PMID: 16778987.
      View in: PubMed
    161. Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. 1983. J Immunol. 2006 Mar 01; 176(5):2683-90. PMID: 16493022.
      View in: PubMed
    162. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006 Apr; 18(2):206-13. PMID: 16464564.
      View in: PubMed
    163. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006; 90:297-339. PMID: 16730267.
      View in: PubMed
    164. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006 Feb 09; 439(7077):682-7. PMID: 16382236.
      View in: PubMed
    165. Puré E, Allison JP, Schreiber RD. Breaking down the barriers to cancer immunotherapy. Nat Immunol. 2005 Dec; 6(12):1207-10. PMID: 16369561.
      View in: PubMed
    166. Williams JA, Hathcock KS, Klug D, Harada Y, Choudhury B, Allison JP, Abe R, Hodes RJ. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J Immunol. 2005 Oct 01; 175(7):4199-207. PMID: 16177059.
      View in: PubMed
    167. Peggs KS, Allison JP. Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. Br J Haematol. 2005 Sep; 130(6):809-24. PMID: 16156851.
      View in: PubMed
    168. Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen JE, Allison JP. Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection. Proc Natl Acad Sci U S A. 2005 Jul 12; 102(28):9872-7. PMID: 15994233.
      View in: PubMed
    169. Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP, Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005 Feb 15; 174(4):1922-31. PMID: 15699119.
      View in: PubMed
    170. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. 1982. J Immunol. 2005 Feb 01; 174(3):1144-51. PMID: 15661866.
      View in: PubMed
    171. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):728-34. PMID: 15701862.
      View in: PubMed
    172. Roden AC, Moser MT, Tri SD, Mercader M, Kuntz SM, Dong H, Hurwitz AA, McKean DJ, Celis E, Leibovich BC, Allison JP, Kwon ED. Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol. 2004 Nov 15; 173(10):6098-108. PMID: 15528346.
      View in: PubMed
    173. Mulé JJ, Weber JS. Translation of cancer immunotherapies. Nat Med. 2004 Nov; 10(11):1153; author reply 1153-4. PMID: 15516900.
      View in: PubMed
    174. Pardoll D, Allison J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nat Med. 2004 Sep; 10(9):887-92. PMID: 15340404.
      View in: PubMed
    175. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity. 2004 Sep; 21(3):401-13. PMID: 15357951.
      View in: PubMed
    176. Loke P, Allison JP. Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells. Arthritis Res Ther. 2004; 6(5):208-14. PMID: 15380035.
      View in: PubMed
    177. Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904. PMID: 15136557.
      View in: PubMed
    178. Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patiño JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16; 22(13-14):1700-8. PMID: 15068853.
      View in: PubMed
    179. Mamura M, Lee W, Sullivan TJ, Felici A, Sowers AL, Allison JP, Letterio JJ. CD28 disruption exacerbates inflammation in Tgf-beta1-/- mice: in vivo suppression by CD4+CD25+ regulatory T cells independent of autocrine TGF-beta1. Blood. 2004 Jun 15; 103(12):4594-601. PMID: 15016653.
      View in: PubMed
    180. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol. 2004 Jan 01; 172(1):34-9. PMID: 14688306.
      View in: PubMed
    181. Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A. 2003 Sep 02; 100(18):10388-92. PMID: 12920180.
      View in: PubMed
    182. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7. PMID: 12826605.
      View in: PubMed
    183. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003 Jul; 4(7):670-9. PMID: 12796776.
      View in: PubMed
    184. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003 Apr 29; 100(9):5336-41. PMID: 12697896.
      View in: PubMed
    185. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry-Spires R, MacRae S, Willman A, Padera R, Jaklitsch MT, Shankar S, Chen TC, Korman A, Allison JP, Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7. PMID: 12682289.
      View in: PubMed
    186. Hurwitz AA, Yanover P, Markowitz M, Allison JP, Kwon ED. Prostate cancer: advances in immunotherapy. BioDrugs. 2003; 17(2):131-8. PMID: 12641491.
      View in: PubMed
    187. Prilliman KR, Lemmens EE, Palioungas G, Wolfe TG, Allison JP, Sharpe AH, Schoenberger SP. Cutting edge: a crucial role for B7-CD28 in transmitting T help from APC to CTL. J Immunol. 2002 Oct 15; 169(8):4094-7. PMID: 12370335.
      View in: PubMed
    188. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol. 2002 Oct; 14(5):666-72. PMID: 12183170.
      View in: PubMed
    189. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002 Jul; 3(7):611-8. PMID: 12087419.
      View in: PubMed
    190. Chambers CA, Kang J, Wu Y, Held W, Raulet DH, Allison JP. The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptor. Blood. 2002 Jun 15; 99(12):4509-16. PMID: 12036882.
      View in: PubMed
    191. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A. 2002 Mar 05; 99(5):3013-7. PMID: 11867713.
      View in: PubMed
    192. Egen JG, Allison JP. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity. 2002 Jan; 16(1):23-35. PMID: 11825563.
      View in: PubMed
    193. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED. The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol. 2001 Nov; Chapter 20:Unit 20.5. PMID: 18432778.
      View in: PubMed
    194. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001 Sep 17; 194(6):823-32. PMID: 11560997.
      View in: PubMed
    195. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001 Aug 20; 194(4):481-9. PMID: 11514604.
      View in: PubMed
    196. Sullivan TJ, Letterio JJ, van Elsas A, Mamura M, van Amelsfort J, Sharpe S, Metzler B, Chambers CA, Allison JP. Lack of a role for transforming growth factor-beta in cytotoxic T lymphocyte antigen-4-mediated inhibition of T cell activation. Proc Natl Acad Sci U S A. 2001 Feb 27; 98(5):2587-92. PMID: 11226283.
      View in: PubMed
    197. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001 Jan 04; 409(6816):97-101. PMID: 11343121.
      View in: PubMed
    198. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19:565-94. PMID: 11244047.
      View in: PubMed
    199. Kuhns MS, Epshteyn V, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates the size, reactivity, and function of a primed pool of CD4+ T cells. Proc Natl Acad Sci U S A. 2000 Nov 07; 97(23):12711-6. PMID: 11050166.
      View in: PubMed
    200. Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):12204-9. PMID: 11035773.
      View in: PubMed
    201. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000 May 01; 60(9):2444-8. PMID: 10811122.
      View in: PubMed
    202. Yu X, Fournier S, Allison JP, Sharpe AH, Hodes RJ. The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol. 2000 Apr 01; 164(7):3543-53. PMID: 10725709.
      View in: PubMed
    203. Piganelli JD, Poulin M, Martin T, Allison JP, Haskins K. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. J Autoimmun. 2000 Mar; 14(2):123-31. PMID: 10677243.
      View in: PubMed
    204. Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, Burg MB. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999 Dec 21; 96(26):15074-9. PMID: 10611340.
      View in: PubMed
    205. Sotomayor EM, Borrello I, Tubb E, Allison JP, Levitsky HI. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A. 1999 Sep 28; 96(20):11476-81. PMID: 10500201.
      View in: PubMed
    206. Krummel MF, Heath WR, Allison J. Differential coupling of second signals for cytotoxicity and proliferation in CD8+ T cell effectors: amplification of the lytic potential by B7. J Immunol. 1999 Sep 15; 163(6):2999-3006. PMID: 10477562.
      View in: PubMed
    207. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999 Aug 02; 190(3):355-66. PMID: 10430624.
      View in: PubMed
    208. Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8603-8. PMID: 10411922.
      View in: PubMed
    209. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999 May 15; 162(10):5813-20. PMID: 10229815.
      View in: PubMed
    210. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol. 1999 Apr; 11(2):203-10. PMID: 10209159.
      View in: PubMed
    211. Chambers CA, Allison JP. CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. Cold Spring Harb Symp Quant Biol. 1999; 64:303-12. PMID: 11232300.
      View in: PubMed
    212. Chambers CA, Sullivan TJ, Truong T, Allison JP. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur J Immunol. 1998 10; 28(10):3137-43. PMID: 9808182.
      View in: PubMed
    213. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A. 1998 Aug 18; 95(17):10067-71. PMID: 9707601.
      View in: PubMed
    214. Rathmell JC, Fournier S, Weintraub BC, Allison JP, Goodnow CC. Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4(+) T cells. J Exp Med. 1998 Aug 17; 188(4):651-9. PMID: 9705947.
      View in: PubMed
    215. Allison J. In memoriam Marian Koshland 1921-1997. J Immunol. 1998 Jul 15; 161(2):545-6. PMID: 9687240.
      View in: PubMed
    216. Hurwitz AA, Townsend SE, Yu TF, Wallin JA, Allison JP. Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma. Int J Cancer. 1998 Jul 03; 77(1):107-13. PMID: 9639401.
      View in: PubMed
    217. Lühder F, Höglund P, Allison JP, Benoist C, Mathis D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med. 1998 Feb 02; 187(3):427-32. PMID: 9449722.
      View in: PubMed
    218. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found Symp. 1998; 215:92-8; discussion 98-102, 186-90. PMID: 9760573.
      View in: PubMed
    219. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JF. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J Exp Med. 1997 Dec 15; 186(12):2057-62. PMID: 9396776.
      View in: PubMed
    220. Chambers CA, Sullivan TJ, Allison JP. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity. 1997 Dec; 7(6):885-95. PMID: 9430233.
      View in: PubMed
    221. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol. 1997 Oct 01; 159(7):3460-73. PMID: 9317145.
      View in: PubMed
    222. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997 Oct; 7(4):445-50. PMID: 9354465.
      View in: PubMed
    223. Zhang Y, Allison JP. Interaction of CTLA-4 with AP50, a clathrin-coated pit adaptor protein. Proc Natl Acad Sci U S A. 1997 Aug 19; 94(17):9273-8. PMID: 9256472.
      View in: PubMed
    224. Chambers CA, Cado D, Truong T, Allison JP. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A. 1997 Aug 19; 94(17):9296-301. PMID: 9256476.
      View in: PubMed
    225. Kwon ED, Hurwitz AA, Foster BA, Madias C, Feldhaus AL, Greenberg NM, Burg MB, Allison JP. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A. 1997 Jul 22; 94(15):8099-103. PMID: 9223321.
      View in: PubMed
    226. Liao XC, Fournier S, Killeen N, Weiss A, Allison JP, Littman DR. Itk negatively regulates induction of T cell proliferation by CD28 costimulation. J Exp Med. 1997 Jul 21; 186(2):221-8. PMID: 9221751.
      View in: PubMed
    227. Nussenzweig M, Allison JP. Lymphocyte activation and effector functions. How signals are integrated in the immune system. Curr Opin Immunol. 1997 Jun; 9(3):293-5. PMID: 9203423.
      View in: PubMed
    228. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol. 1997 Jun; 9(3):396-404. PMID: 9203422.
      View in: PubMed
    229. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol. 1997 Mar; 73(1-2):57-62. PMID: 9058759.
      View in: PubMed
    230. Fournier S, Rathmell JC, Goodnow CC, Allison JP. T cell-mediated elimination of B7.2 transgenic B cells. Immunity. 1997 Mar; 6(3):327-39. PMID: 9075933.
      View in: PubMed
    231. Chambers CA, Allison JP. The role of tyrosine phosphorylation and PTP-1C in CTLA-4 signal transduction. Eur J Immunol. 1996 Dec; 26(12):3224-9. PMID: 8977326.
      View in: PubMed
    232. Kay TW, Parker JL, Stephens LA, Thomas HE, Allison J. RIP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol. 1996 Oct 15; 157(8):3688-93. PMID: 8871671.
      View in: PubMed
    233. Chambers CA, Krummel MF, Boitel B, Hurwitz A, Sullivan TJ, Fournier S, Cassell D, Brunner M, Allison JP. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev. 1996 Oct; 153:27-46. PMID: 9010718.
      View in: PubMed
    234. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996 Jun 01; 183(6):2533-40. PMID: 8676074.
      View in: PubMed
    235. Krummel MF, Sullivan TJ, Allison JP. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 1996 Apr; 8(4):519-23. PMID: 8671638.
      View in: PubMed
    236. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22; 271(5256):1734-6. PMID: 8596936.
      View in: PubMed
    237. Liu B, Podack ER, Allison JP, Malek TR. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. J Immunol. 1996 Feb 01; 156(3):1117-25. PMID: 8557987.
      View in: PubMed
    238. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science. 1995 Nov 10; 270(5238):932-3. PMID: 7481795.
      View in: PubMed
    239. Allison JP, Hurwitz AA, Leach DR. Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol. 1995 Oct; 7(5):682-6. PMID: 8573312.
      View in: PubMed
    240. Zhang Y, Cado D, Asarnow DM, Komori T, Alt FW, Raulet DH, Allison JP. The role of short homology repeats and TdT in generation of the invariant gamma delta antigen receptor repertoire in the fetal thymus. Immunity. 1995 Oct; 3(4):439-47. PMID: 7584135.
      View in: PubMed
    241. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995 Aug 01; 182(2):459-65. PMID: 7543139.
      View in: PubMed
    242. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today. 1995 Jul; 16(7):306-10. PMID: 7576059.
      View in: PubMed
    243. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 1994 Dec 15; 54(24):6477-83. PMID: 7527298.
      View in: PubMed
    244. Allison JP. CD28-B7 interactions in T-cell activation. Curr Opin Immunol. 1994 Jun; 6(3):414-9. PMID: 7522466.
      View in: PubMed
    245. Nandi D, Gross JA, Allison JP. CD28-mediated costimulation is necessary for optimal proliferation of murine NK cells. J Immunol. 1994 Apr 01; 152(7):3361-9. PMID: 7511644.
      View in: PubMed
    246. Holsti MA, McArthur J, Allison JP, Raulet DH. Role of IL-6, IL-1, and CD28 signaling in responses of mouse CD4+ T cells to immobilized anti-TCR monoclonal antibody. J Immunol. 1994 Feb 15; 152(4):1618-28. PMID: 7907103.
      View in: PubMed
    247. Clements JL, Winslow G, Donahue C, Cooper SM, Allison JP, Budd RC. Co-stimulation via CD28 induces activation of a refractory subset of MRL-lpr/lpr T lymphocytes. Int Immunol. 1993 Nov; 5(11):1451-60. PMID: 7903158.
      View in: PubMed
    248. Nandi D, Allison JP. Characterization of neutrophils and T lymphocytes associated with the murine vaginal epithelium. Reg Immunol. 1993 Nov-Dec; 5(6):332-8. PMID: 8068536.
      View in: PubMed
    249. Sagerström CG, Kerr EM, Allison JP, Davis MM. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci U S A. 1993 Oct 01; 90(19):8987-91. PMID: 8415642.
      View in: PubMed
    250. Page DM, Kane LP, Allison JP, Hedrick SM. Two signals are required for negative selection of CD4+CD8+ thymocytes. J Immunol. 1993 Aug 15; 151(4):1868-80. PMID: 7688388.
      View in: PubMed
    251. Giese T, Allison JP, Davidson WF. Functionally anergic lpr and gld B220+ T cell receptor (TCR)-alpha/beta+ double-negative T cells express CD28 and respond to costimulation with phorbol myristate acetate and antibodies to CD28 and the TCR. J Immunol. 1993 Jul 15; 151(2):597-609. PMID: 7687618.
      View in: PubMed
    252. Leclercq G, Plum J, Nandi D, De Smedt M, Allison JP. Intrathymic differentiation of V gamma 3 T cells. J Exp Med. 1993 Jul 01; 178(1):309-15. PMID: 8315386.
      View in: PubMed
    253. Harding FA, Allison JP. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med. 1993 Jun 01; 177(6):1791-6. PMID: 7684435.
      View in: PubMed
    254. Wells FB, Tatsumi Y, Bluestone JA, Hedrick SM, Allison JP, Matis LA. Phenotypic and functional analysis of positive selection in the gamma/delta T cell lineage. J Exp Med. 1993 Apr 01; 177(4):1061-70. PMID: 8459203.
      View in: PubMed
    255. Allison JP. Gamma delta T-cell development. Curr Opin Immunol. 1993 Apr; 5(2):241-6. PMID: 8389558.
      View in: PubMed
    256. Gramzinski RA, Adams E, Gross JA, Goodman TG, Allison JP, Lefrançois L. T cell receptor-triggered activation of intraepithelial lymphocytes in vitro. Int Immunol. 1993 Feb; 5(2):145-53. PMID: 8383994.
      View in: PubMed
    257. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993 Jan 15; 259(5093):368-70. PMID: 7678351.
      View in: PubMed
    258. Heath WR, Allison J, Miller JF. CD8+ T cell tolerance and autoimmunity to extra-thymic antigens. Autoimmunity. 1993; 15(4):293-8. PMID: 8136457.
      View in: PubMed
    259. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol. 1992 Jul 15; 149(2):380-8. PMID: 1320641.
      View in: PubMed
    260. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992 Apr 16; 356(6370):607-9. PMID: 1313950.
      View in: PubMed
    261. Nandi D, Allison JP. Phenotypic analysis and gamma delta-T cell receptor repertoire of murine T cells associated with the vaginal epithelium. J Immunol. 1991 Sep 15; 147(6):1773-8. PMID: 1679835.
      View in: PubMed
    262. Havran WL, Chien YH, Allison JP. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science. 1991 Jun 07; 252(5011):1430-2. PMID: 1828619.
      View in: PubMed
    263. Iwashima M, Green A, Bonyhadi M, Davis MM, Allison JP, Chien YH. Expression of a fetal gamma delta T-cell receptor in adult mice triggers a non-MHC-linked form of selective depletion. Int Immunol. 1991 Apr; 3(4):385-93. PMID: 1831656.
      View in: PubMed
    264. Glaichenhaus N, Davis C, Bornschlegel K, Allison JP, Shastri N. A novel strategy for the generation of T cell lines lacking expression of endogenous alpha- and/or beta-chain T cell receptor genes. J Immunol. 1991 Apr 01; 146(7):2095-101. PMID: 1826016.
      View in: PubMed
    265. Allison J. Introduction: gamma delta T cells--the 'other' T lymphocytes. Semin Immunol. 1991 Mar; 3(2):73-4. PMID: 1832319.
      View in: PubMed
    266. Havran WL, Carbone A, Allison JP. Murine T cells with invariant gamma delta antigen receptors: origin, repertoire, and specificity. Semin Immunol. 1991 Mar; 3(2):89-97. PMID: 1716172.
      View in: PubMed
    267. Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. Annu Rev Immunol. 1991; 9:679-705. PMID: 1832874.
      View in: PubMed
    268. Allison JP, Asarnow DM, Bonyhadi M, Carbone A, Havran WL, Nandi D, Noble J. Gamma delta T cells in murine epithelia: origin, repertoire, and function. Adv Exp Med Biol. 1991; 292:63-9. PMID: 1835264.
      View in: PubMed
    269. Lotscher E, Allison JP. Nucleotide and deduced amino acid sequence of a murine cDNA clone encoding one member of the hsp65 multigene family. Nucleic Acids Res. 1990 Dec 11; 18(23):7153. PMID: 2263486.
      View in: PubMed
    270. Mitchell DL, Allison JP, Nairn RS. Immunoprecipitation of pyrimidine(6-4)pyrimidone photoproducts and cyclobutane pyrimidine dimers in uv-irradiated DNA. Radiat Res. 1990 Sep; 123(3):299-303. PMID: 2217727.
      View in: PubMed
    271. Ferrick DA, Chan A, Rahemtulla A, Widacki SM, Xia M, Broughton H, Gajewski DA, Ballhausen W, Allison JP, Bluestone JA, et al. Expression of a T cell receptor gamma-chain (V gamma 1.1J gamma 4C gamma 4) transgene in mice influences T cell receptor ontogeny and thymic architecture during development. J Immunol. 1990 Jul 01; 145(1):20-7. PMID: 2141615.
      View in: PubMed
    272. Riegel JS, Richie ER, Allison JP. Nuclear events after activation of CD4+8+ thymocytes. J Immunol. 1990 May 01; 144(9):3611-8. PMID: 1970353.
      View in: PubMed
    273. Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol. 1990 Apr 15; 144(8):3201-10. PMID: 2157764.
      View in: PubMed
    274. Havran WL, Allison JP. Origin of Thy-1+ dendritic epidermal cells of adult mice from fetal thymic precursors. Nature. 1990 Mar 01; 344(6261):68-70. PMID: 1968230.
      View in: PubMed
    275. Allison JP, Raulet DH. The immunobiology of gamma delta+ T cells. Semin Immunol. 1990 Jan; 2(1):59-65. PMID: 2151798.
      View in: PubMed
    276. Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor repertoires of two classes of murine epithelium-associated T cells. Nature. 1989 Sep 07; 341(6237):60-2. PMID: 2528075.
      View in: PubMed
    277. Strober S, Dejbachsh-Jones S, Van Vlasselaer P, Duwe G, Salimi S, Allison JP. Cloned natural suppressor cell lines express the CD3+CD4-CD8- surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol. 1989 Aug 15; 143(4):1118-22. PMID: 2526181.
      View in: PubMed
    278. Havran WL, Grell S, Duwe G, Kimura J, Wilson A, Kruisbeek AM, O'Brien RL, Born W, Tigelaar RE, Allison JP. Limited diversity of T-cell receptor gamma-chain expression of murine Thy-1+ dendritic epidermal cells revealed by V gamma 3-specific monoclonal antibody. Proc Natl Acad Sci U S A. 1989 Jun; 86(11):4185-9. PMID: 2726770.
      View in: PubMed
    279. Kyewski BA, Schirrmacher V, Allison JP. Antibodies against the T cell receptor/CD3 complex interfere with distinct intra-thymic cell-cell interactions in vivo: correlation with arrest of T cell differentiation. Eur J Immunol. 1989 May; 19(5):857-63. PMID: 2525475.
      View in: PubMed
    280. Duplay P, Lancki D, Allison JP. Distribution and ontogeny of CD2 expression by murine T cells. J Immunol. 1989 May 01; 142(9):2998-3005. PMID: 2565352.
      View in: PubMed
    281. Havran WL, Poenie M, Tigelaar RE, Tsien RY, Allison JP. Phenotypic and functional analysis of gamma delta T cell receptor-positive murine dendritic epidermal clones. J Immunol. 1989 Mar 01; 142(5):1422-8. PMID: 2783942.
      View in: PubMed
    282. Nairn RS, McIntyre BW, Richie ER, Allison JP. Characterization of env gene recombination in x-ray--induced thymomas of C57BL/6 mice. Mol Carcinog. 1989; 2(3):126-30. PMID: 2675902.
      View in: PubMed
    283. Groghan TW, Davignon JL, Evans J, Allison JP, Eisenberg RA, Frelinger JA, Cohen PL. Diminished expression of the T cell receptor on the expanded lymphocyte population in MRL/Mp-lpr/lpr mice. Autoimmunity. 1989; 2(2):97-111. PMID: 2562377.
      View in: PubMed
    284. Marusic-Galesic S, Saito T, Tentori L, Zuñiga-Pflucker J, Raulet DH, Allison JP, Kruisbeek AM. A novel gamma delta T cell receptor for antigen adds limited diversity to the gamma delta repertoire in adult thymus. J Immunol. 1989 Jan 01; 142(1):28-34. PMID: 2521236.
      View in: PubMed
    285. Asarnow DM, Kuziel WA, Bonyhadi M, Tigelaar RE, Tucker PW, Allison JP. Limited diversity of gamma delta antigen receptor genes of Thy-1+ dendritic epidermal cells. Cell. 1988 Dec 02; 55(5):837-47. PMID: 2847872.
      View in: PubMed
    286. Havran WL, Allison JP. Developmentally ordered appearance of thymocytes expressing different T-cell antigen receptors. Nature. 1988 Sep 29; 335(6189):443-5. PMID: 2458531.
      View in: PubMed
    287. Richie ER, McEntire B, Phillips J, Allison JP. Altered expression of lymphocyte differentiation antigens on phorbol ester-activated CD4+8+ T cells. J Immunol. 1988 Jun 15; 140(12):4115-22. PMID: 3259607.
      View in: PubMed
    288. Richie ER, McEntire B, Crispe N, Kimura J, Lanier LL, Allison JP. Alpha/beta T-cell antigen receptor gene and protein expression occurs at early stages of thymocyte differentiation. Proc Natl Acad Sci U S A. 1988 Feb; 85(4):1174-8. PMID: 2963339.
      View in: PubMed
    289. Allison JP, Havran WL, Asarnow D, Tigelaar RE, Tucker PW, Bonyhadi M. Gamma delta antigen receptors of Thy-1+ dendritic epidermal cells: implications for thymic differentiation. Immunol Res. 1988; 7(4):292-302. PMID: 2906352.
      View in: PubMed
    290. Bonyhadi M, Weiss A, Tucker PW, Tigelaar RE, Allison JP. Delta is the Cx-gene product in the gamma/delta antigen receptor of dendritic epidermal cells. Nature. 1987 Dec 10-16; 330(6148):574-6. PMID: 3500417.
      View in: PubMed
    291. Crispe IN, Shimonkevitz RP, Husmann LA, Kimura J, Allison JP. Expression of T cell antigen receptor beta-chains on subsets of mouse thymocytes. Analysis by three-color flow cytometry. J Immunol. 1987 Dec 01; 139(11):3585-9. PMID: 2960738.
      View in: PubMed
    292. Lanier LL, Serafini AT, Ruitenberg JJ, Cwirla S, Federspiel NA, Phillips JH, Allison JP, Weiss A. The gamma T-cell antigen receptor. J Clin Immunol. 1987 Nov; 7(6):429-40. PMID: 3320076.
      View in: PubMed
    293. Havran WL, Poenie M, Kimura J, Tsien R, Weiss A, Allison JP. Expression and function of the CD3-antigen receptor on murine CD4+8+ thymocytes. Nature. 1987 Nov 12-18; 330(6144):170-3. PMID: 2959867.
      View in: PubMed
    294. Kuziel WA, Takashima A, Bonyhadi M, Bergstresser PR, Allison JP, Tigelaar RE, Tucker PW. Regulation of T-cell receptor gamma-chain RNA expression in murine Thy-1+ dendritic epidermal cells. Nature. 1987 Jul 16-22; 328(6127):263-6. PMID: 2885757.
      View in: PubMed
    295. O'Neill HC, McGrath MS, Allison JP, Weissman IL. A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukemia cell binding of its cognate retrovirus. Cell. 1987 Apr 10; 49(1):143-51. PMID: 2435413.
      View in: PubMed
    296. Lanier LL, Federspiel NA, Ruitenberg JJ, Phillips JH, Allison JP, Littman D, Weiss A. The T cell antigen receptor complex expressed on normal peripheral blood CD4-, CD8- T lymphocytes. A CD3-associated disulfide-linked gamma chain heterodimer. J Exp Med. 1987 Apr 01; 165(4):1076-94. PMID: 2435832.
      View in: PubMed
    297. Nagasawa R, Gross J, Kanagawa O, Townsend K, Lanier LL, Chiller J, Allison JP. Identification of a novel T cell surface disulfide-bonded dimer distinct from the alpha/beta antigen receptor. J Immunol. 1987 Feb 01; 138(3):815-24. PMID: 2433330.
      View in: PubMed
    298. Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol. 1987; 5:503-40. PMID: 2439105.
      View in: PubMed
    299. Lanier LL, Allison JP, Phillips JH. Correlation of cell surface antigen expression on human thymocytes by multi-color flow cytometric analysis: implications for differentiation. J Immunol. 1986 Oct 15; 137(8):2501-7. PMID: 3531334.
      View in: PubMed
    300. Lanier LL, Ruitenberg JJ, Allison JP, Weiss A. Distinct epitopes on the T cell antigen receptor of HPB-ALL tumor cells identified by monoclonal antibodies. J Immunol. 1986 Oct 01; 137(7):2286-92. PMID: 2428866.
      View in: PubMed
    301. Saunders PH, McIntyre BW, Lawlor DA, Bridges WJ, Allison JP. The congenic mutant B6.C-H-2bm-1 (H-2bm-1) serological response to the T-cell receptor on EL4. Cell Immunol. 1986 Sep; 101(2):586-92. PMID: 3757049.
      View in: PubMed
    302. Allison JP, McIntyre BW, Ridge LL, Gross-Pelose J, Lanier LL. Molecular characterization of the murine T cell antigen receptor and associated structures. Fed Proc. 1985 Oct; 44(13):2870-3. PMID: 2412897.
      View in: PubMed
    303. Hixson DC, Allison JP. Monoclonal antibodies recognizing oval cells induced in the liver of rats by N-2-fluorenylacetamide or ethionine in a choline-deficient diet. Cancer Res. 1985 Aug; 45(8):3750-60. PMID: 2410100.
      View in: PubMed
    304. Walborg EF, Tsuchida S, Weeden DS, Thomas MW, Barrick A, McEntire KD, Allison JP, Hixson DC. Identification of dipeptidyl peptidase IV as a protein shared by the plasma membrane of hepatocytes and liver biomatrix. Exp Cell Res. 1985 Jun; 158(2):509-18. PMID: 3891389.
      View in: PubMed
    305. Allison JP, Lanier LL. Identification of antigen receptor-associated structures on murine T cells. Nature. 1985 Mar 7-13; 314(6006):107-9. PMID: 2579338.
      View in: PubMed
    306. Allison JP, Ridge L, Lund J, Gross-Pelose J, Lanier L, McIntyre BW. The murine T cell antigen receptor and associated structures. Immunol Rev. 1984 Oct; 81:145-60. PMID: 6210241.
      View in: PubMed
    307. McIntyre BW, Allison JP. Biosynthesis and processing of murine T-cell antigen receptor. Cell. 1984 Oct; 38(3):659-65. PMID: 6488315.
      View in: PubMed
    308. Kline K, Allison JP, McIntyre BW, Sanders BG. Immunochemical characterization of differentiation and age-related cell surface antigens expressed by chicken erythrocytes. Cancer Res. 1984 Aug; 44(8):3576-83. PMID: 6378372.
      View in: PubMed
    309. Hixson DC, DeLourdes Ponce M, Allison JP, Walborg EF. Cell surface expression by adult rat hepatocytes of a non-collagen glycoprotein present in rat liver biomatrix. Exp Cell Res. 1984 Jun; 152(2):402-14. PMID: 6723795.
      View in: PubMed
    310. Hixson DC, Allison JP, McEntire KD, Nairn RS, Chesner JE, Walborg EF. Structural differences in envelope glycoproteins associated with rat leukaemia virus produced by Novikoff hepatocellular carcinoma and spontaneously transformed Wistar rat embryo cells. J Gen Virol. 1984 Apr; 65 ( Pt 4):743-60. PMID: 6368746.
      View in: PubMed
    311. Pellegrino MA, Russo C, Allison JP. HLA antigens in serum. Methods Enzymol. 1984; 108:614-24. PMID: 6527659.
      View in: PubMed
    312. Kappler J, Kubo R, Haskins K, Hannum C, Marrack P, Pigeon M, McIntyre B, Allison J, Trowbridge I. The major histocompatibility complex-restricted antigen receptor on T cells in mouse and man: identification of constant and variable peptides. Cell. 1983 Nov; 35(1):295-302. PMID: 6605199.
      View in: PubMed
    313. McIntyre BW, Allison JP. The mouse T cell receptor: structural heterogeneity of molecules of normal T cells defined by xenoantiserum. Cell. 1983 Oct; 34(3):739-46. PMID: 6194888.
      View in: PubMed
    314. Hixson DC, Allison JP, Chesner JE, Leger MJ, Ridge LL, Walborg EF. Characterization of a family of glycoproteins associated with the bile canalicular membrane of normal hepatocytes but not expressed by two transplantable rat hepatocellular carcinomas. Cancer Res. 1983 Aug; 43(8):3874-84. PMID: 6344992.
      View in: PubMed
    315. Lanier LL, Richie ER, Howell AL, Allison JP. Expression of Ly-1 and Ly-2 on a spontaneous AKR B-cell lymphoma. Immunogenetics. 1983; 17(6):655-9. PMID: 6602763.
      View in: PubMed
    316. Callahan GN, Pardi D, Giedlin MA, Allison JP, Morizot DM, Martin WJ. Biochemical evidence for expression of a semi-allogeneic, H-2 antigen by a murine adenocarcinoma. J Immunol. 1983 Jan; 130(1):471-9. PMID: 6847892.
      View in: PubMed
    317. Nelson CH, Allison JP, Kline K, Sanders BG. Chicken fetal and adult antigen expression on erythroleukemia cells before and after induced differentiation. Cancer Res. 1982 Nov; 42(11):4625-30. PMID: 7127300.
      View in: PubMed
    318. Sanders BG, Allison JP, Kline K. Monoclonal antibody to chicken fetal antigens on normal erythroid cells and hematopoietic-lymphoid tumor cell lines. Cancer Res. 1982 Nov; 42(11):4532-9. PMID: 6751524.
      View in: PubMed
    319. Allison JP, McIntyre BW, Bloch D. Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody. J Immunol. 1982 Nov; 129(5):2293-300. PMID: 6181166.
      View in: PubMed
    320. Kline K, Allison JP, Sanders BG. Chemical and immunological characterization of developmentally expressed chicken erythroid surface membrane antigens. Dev Biol. 1982 Jun; 91(2):389-96. PMID: 6178635.
      View in: PubMed
    321. LeGrue SJ, Allison JP, Macek CM, Pellis NR, Kahan BD. Immunobiological properties of 1-butanol-extracted cell surface antigens. Cancer Res. 1981 Oct; 41(10):3956-60. PMID: 7026027.
      View in: PubMed
    322. Glenney JR, Allison JP, Hixson DC, Walborg EF. Resolution and partial characterization of the major plasma membrane sialoglycoproteins of Novikoff tumor cells. J Biol Chem. 1979 Sep 25; 254(18):9247-53. PMID: 479193.
      View in: PubMed
    323. Callahan GN, Allison JP, Pellegrino MA, Reisfeld RA. Physical association of histocompatibility antigens and tumor-associated antigens on the surface of murine lymphoma cells. J Immunol. 1979 Jan; 122(1):70-4. PMID: 762424.
      View in: PubMed
    324. Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. Transplantation. 1978 Dec; 26(6):451-4. PMID: 569916.
      View in: PubMed
    325. Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A. 1978 Aug; 75(8):3953-6. PMID: 99745.
      View in: PubMed
    326. Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. J Immunol. 1978 Aug; 121(2):579-85. PMID: 681750.
      View in: PubMed
    327. Callahan GN, Allison JP. H-2 antigens on a murine lymphoma are associated with additional proteins. Nature. 1978 Jan 12; 271(5641):165-7. PMID: 74802.
      View in: PubMed
    328. Ferrone S, Allison JP, Pellegrino MA. Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol. 1978; 7:239-81. PMID: 103685.
      View in: PubMed
    329. Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA antisera. Transplant Proc. 1977 Dec; 9(4):1691-3. PMID: 74875.
      View in: PubMed
    330. Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplant Proc. 1977 Mar; 9(1):601-4. PMID: 194373.
      View in: PubMed
    331. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol. 1977 Mar; 118(3):1004-9. PMID: 191523.
      View in: PubMed
    332. Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation. 1977 Jan; 23(1):7-15. PMID: 65035.
      View in: PubMed
    333. Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. [Biological and chemical aspects of histocompatibility antigens in serum]. Haematologica. 1976 Dec; 61(4):397-417. PMID: 828605.
      View in: PubMed
    334. Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplant Proc. 1976 Jun; 8(2):173-8. PMID: 59439.
      View in: PubMed
    335. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation. 1975 Nov; 20(5):431-3. PMID: 174256.
      View in: PubMed
    336. Prager MD, Ludden CM, Mandy WJ, Allison JP, Kitto GB. Endotoxin-stimulated immune response to modified lymphoma cells. J Natl Cancer Inst. 1975 Mar; 54(3):773-5. PMID: 1168264.
      View in: PubMed
    337. Allison JP. Training procedures and task difficulty in brightness and position discriminations by rats. Psychol Rep. 1972 Aug; 31(1):71-6. PMID: 5055920.
      View in: PubMed
    338. Allison JP, Davidson L, Gutierrez-Hartman A, Kitto GB. Insolubilization of L-asparaginase by covalent attachment to nylon tubing. Biochem Biophys Res Commun. 1972 Apr 14; 47(1):66-73. PMID: 5027141.
      View in: PubMed
    339. Monoclonal antibodies in cancer therapy. Cancer Immunity. 12.
    340. ICOS promotes the function of CD4+ effector T cells during anti-OX40-mediated tumor rejection. Cancer Research. 76:3684-3689.
    341. Cancer. Current Opinion in Immunology. 12:569-570.
    342. Anticancer immunotherapy by CTLA-4 blockade. Cell Research. 25:208-224.
    343. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discovery. 5:861-878.
    344. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. 13:412-424.
    345. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 6:827-837.
    346. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nature Communications. 7.
    347. Erratum. Journal of Immunology. 172:5128.
    348. The T-cell antigen receptor gamma gene. Immunology Today. 8:293-296.
    349. Charge heterogeneity of dipeptidyl peptidase IV (DPP IV) from rat liver, kidney and a hepatocellular carcinoma. Federation Proceedings. 43.
    350. Biosynthesis of the murine T cell antigen receptor. Federation Proceedings. 43.
    351. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immunity. 10.
    352. Correlation of antigen receptor expression and surface phenotype of murine T-lymphomas. Federation Proceedings. 44.
    353. Erratum to Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival [Cancer Cell 25, 719-734; (2014)]. Cancer Cell. 28:831-833.
    354. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. OncoImmunology. 1:544-546.
    355. Phenotypic characterization of allogeneically transplanted oval cells.
    356. Erratum. Journal of Immunology. 173:2199.
    357. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer immunology research. 4:835-844.
    358. Immune co-signaling to treat cancer. 211-280.
    359. Erratum. Journal of Immunology. 169:6056.
    360. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clinical Cancer Research. 22:5729-5737.
    361. Induction of CNS inflammatory disease as a consequence of CTLA-4/B7 blockade. FASEB Journal. 12.
    362. Molecular characterization of the murine T cell antigen receptor and associated structures. Federation Proceedings. 43.
    363. Anti-CTLA4 in the immunotherapy of malignancies. European Journal of Cancer. 37.
    364. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167:397-404.e9.
    365. Response to comment on "Expression of Helios in peripherally induced Foxp3 + regulatory T cells". Journal of Immunology. 189:500-501.
    366. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. FASEB Journal. 12.
    367. Erratum. Cancer Immunity. 10.
    368. Congenic mutant recognition of the T cell heteroduplex idiotype on EL4 lymphoma. Federation Proceedings. 43.
    369. The substrate specificity of L-asparaginase from Alcaligenes eutrophus. FEBS Letters. 14:107-108.
    370. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 7:967-980.
    371. Anticancer immunotherapy by CTLA-4 blockade. Cell Research. 25:399-400.
    372. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. OncoImmunology. 5.
    373. Blockade of CTLA-4 combined with a GM-CSF vaccine cures mice from the highly tumorigenic, poorly immunogenic melanoma B16-BL6, and induces skin depigmentation. FASEB Journal. 12.
    374. Lack of regulation by CTLA-4 in the autoimmune NOD mouse. FASEB Journal. 12.
    375. Protein Localization in Negative Signaling. 355-359.
    376. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy. Nature Communications. 7.
    377. Effect of murine Vγ3 and Vδ1 antigen receptor transgenes on T cell development. Developmental and Comparative Immunology. 15.
    378. T cell-mediated tumor immunity in a murine model of mammary carcinoma. FASEB Journal. 10.
    379. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proceedings of the National Academy of Sciences of the United States of America. 113:11919-11924.
    380. Checkpoint blockade and combinatorial immunotherapies. 363-390.
    381. Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease. Journal of Hematology and Oncology. 9.
    382. Ablation of B7-H3 but not B7-H4 results in highly increased tumor burden in a murine model of spontaneous prostate cancer. Cancer immunology research. 3:849-854.
    ALLISON's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description